Drug profile · INN
prochlorperazine
APO-PROCHLORPERAZINE
prochlorperazine (APO-PROCHLORPERAZINE) is a dopamine d2 receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: rectal. Current US regulatory status: approved.
Drug details — prochlorperazine
- US status
- approved
- Class
- —
- Route
- RECTAL
- Patents
- 4
- Programs
- 2
- Data quality
- 0.84
Quick answer
prochlorperazine (APO-PROCHLORPERAZINE) is a dopamine d2 receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: rectal. Current US regulatory status: approved.
Key facts
Mechanism of action
Dopamine D2 receptor antagonist
Primary target: D(2) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 10369208
Methods for the induction of immune responses in a subject compromising administering virus-like particles (VLPS) prepared from Chikungunya virus structural proteins
granted -
US 9044419
Vaccine compositions compromising βs-crystallin for inducing immune responses against components of drusen
granted -
US 8263091
Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
granted -
US 6444872
Large animal model of invasive pulmonary aspergillosis in an immunocompromised host
expired
Frequently asked questions
What is prochlorperazine?
prochlorperazine (APO-PROCHLORPERAZINE) is a dopamine d2 receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: rectal. Current US regulatory status: approved.
What is the brand name for prochlorperazine?
APO-PROCHLORPERAZINE is a marketed brand name for prochlorperazine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of prochlorperazine?
prochlorperazine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.